Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Abbisko Cayman Limited ( (HK:2256) ) has shared an update.
Abbisko Cayman Limited has announced significant advancements in its drug development pipeline for the first half of 2025. The company’s lead asset, pimicotinib, has reached a major milestone with the acceptance of its NDA by the China NMPA for the treatment of tenosynovial giant cell tumor, and Merck has exercised a global commercialization option for the drug. Additionally, Abbisko has initiated a registrational study for irpagratinib in hepatocellular carcinoma and received Breakthrough Therapy Designation from the China NMPA, underscoring its potential as a precision treatment for HCC.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a biopharmaceutical company focused on the development of innovative therapies for cancer and other diseases. The company specializes in the research and development of targeted therapies, with a market focus on precision medicine for oncology.
Average Trading Volume: 4,499,577
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.91B
For a thorough assessment of 2256 stock, go to TipRanks’ Stock Analysis page.